Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow IDYA by emailGet an email when IDYA pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about IDYA, unsubscribe in one click. Privacy
📣 What IDYA Says Is Next
second half of 2026 · “IDEAYA plans to begin a Phase 1 combination trial in the second half of 2026. o Upon joint IDEAYA and Roche approval, the collaboration may also evaluate a combination triplet with IDE892, RG6505, and IDE397, IDEAYA’s proprietary Phase 1/2 MAT2A inhibitor.”
Company press release, Aug 4, 2026 · SEC filing
by the end of 2026 · “IDE034 (B7H3/PTK7 bispecific TOP1 ADC): IDEAYA plans to provide initial clinical data from its ongoing Phase 1 dose escalation trial by the end of 2026 or early 2027, which is expected to include preliminary safety and efficacy data.”
Company press release, Aug 4, 2026 · SEC filing
by the end of 2026 · “Hengrui is also targeting to initiate a Phase 3 registrational trial for IDE849 in refractory SCLC in China by the end of 2026.”
Company press release, Aug 4, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full IDYA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IDYA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.